Qianhai Health Holdings Limited (0911.HK), an investment holding company incorporated in the Cayman Islands in 2011 and listed on the Main Board of The Stock Exchange of Hong Kong in 2014, principally engages in the trading and sale of electronic component products and health-care products from its headquarters in Sheung Wan, Hong Kong. The company operates through two main segments, offering electronic components such as NAND flash wafers, embed multi-chip package memory, semiconductors, central processing units and general electronic components to customers in consumer electronics, automotive, industrial applications and information technology sectors; and health-care products including Chinese herbal medicines, American ginseng, ginseng wine, healthy drinks, skincare, body-care items and food supplements primarily to wholesalers and retailers in Hong Kong and the People's Republic of China. It maintains a subsidiary relationship with Explorer Rosy Limited and employs a multi-faceted procurement strategy combining back-to-back orders and strategic bulk purchases from branded upstream manufacturers. In recent developments, the company completed a ten-to-one share consolidation effective May 2024 and adopted a new share option scheme in June 2024; disposed of its entire interests in Huge Hope Holdings Limited and its subsidiary on November 28, 2024; reported revenue growth of 11% to HK$340.9 million for the first half of 2025 driven by electronic component sales amid AI, 5G and automotive demand, though gross profit declined due to pricing pressures; and continues negotiating potential investments in manufacturing facilities in the PRC for value-added services, food processing factories for health supplements, and authorised distributorships for health-related products while actively sourcing new offerings in the health-care segment.